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Background Obesity predominantly affects populations in high-income countries and those countries facing
epidemiological transition. The risk of childhood obesity is increased among infants who had overweight or obesity at
birth, but in low-resource settings one in five infants are born small for gestational age. We aimed to study the
relationships between: (1) maternal metabolite signatures; (2) fetal abdominal growth; and (3) postnatal growth,
adiposity, and neurodevelopment.
Methods In the prospective, multinational, observational INTERBIO-21st fetal study, conducted in maternity units in
Pelotas (Brazil), Nairobi (Kenya), Karachi (Pakistan), Soweto (South Africa), Mae Sot (Thailand), and Oxford (UK),
we enrolled women (≥18 years, with a BMI of less than 35 kg/m², natural conception, and a singleton pregnancy) who
initiated antenatal care before 14 weeks’ gestation. Ultrasound scans were performed every 5±1 weeks until delivery to
measure fetal growth and feto–placental blood flow, and we used finite mixture models to derive growth trajectories of
abdominal circumference. The infants’ health, growth, and development were monitored from birth to age 2 years. Early
pregnancy maternal blood and umbilical cord venous blood samples were collected for untargeted metabolomic analysis.
Findings From Feb 8, 2012, to Nov 30, 2019, we enrolled 3598 pregnant women and followed up their infants to 2 years
of age. We identified four ultrasound-derived trajectories of fetal abdominal circumference growth that accelerated or
decelerated within a crucial 20–25 week gestational age window: faltering growth, early accelerating growth, late
accelerating growth, and median growth tracking. These distinct phenotypes had matching feto–placental blood flow
patterns throughout pregnancy, and different growth, adiposity, vision, and neurodevelopment outcomes in early
childhood. There were 709 maternal metabolites with positive effect for the faltering growth phenotype and 54 for the
early accelerating growth phenotype; 31 maternal metabolites had a negative effect for the faltering growth phenotype
and 76 for the early accelerating growth phenotype. Metabolites associated with the faltering growth phenotype had
statistically significant odds ratios close to 1·5 (ie, suggesting upregulation of metabolic pathways of impaired fetal
growth). The metabolites had a reciprocal relationship with the early accelerating growth phenotype, with statistically
significant odds ratios close to 0.6 (ie, suggesting downregulation of fetal growth acceleration). The maternal metabolite
signatures included 5-hydroxy-eicosatetraenoic acid, and 11 phosphatidylcholines linked to oxylipin or saturated fatty
acid sidechains. The fungicide, chlorothalonil, was highly abundant in the early accelerating growth phenotype group.
Interpretation Early pregnancy lipid biology associated with fetal abdominal growth trajectories is an indicator of
patterns of growth, adiposity, vision, and neurodevelopment up to the age of 2 years. Our findings could contribute to
the earlier identification of infants at risk of obesity.
Funding Bill & Melinda Gates Foundation.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Obesity affects populations in most high-income
countries and those undergoing an epidemiological
transition,1 with women of reproductive age and children
overrepresented.2 The risk of childhood obesity is
increased if an infant already has overweight or obesity at
birth.3 Conversely, in low-income and middle-income

countries, one in five infants are born small for
gestational age (SGA).4 The rate of weight gain for infants
in the first 2 postnatal years establishes early childhood
total and abdominal fat mass, and cardiometabolic
disease risk in later life.5
There is increasing evidence that global SGA rates are
associated more with the maternal exposome, including
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022

Articles

Research in context
Evidence before this study
We searched, without any language restriction, Embase,
PubMed, Cochrane, LILACS, NIH, and NHS, from Jan 1, 2001,
to Aug 31, 2021, for “metabolomics”, “metabolites”,
“metabolome”, “proteomics”, “proteome”, and “small for
gestational age”, “intrauterine growth restriction”, “impaired
fetal growth” and “maternal morbidity”. Google Scholar,
proceedings of perinatal congresses, references of identified
studies, and previous reviews were also searched. This search
revealed one cohort and five case–control studies, all with small
sample sizes. Of these, four reported associations with small for
gestational age (SGA), including (1) a 19-metabolite signature
that included phosphatidylcholines and fatty acids;
(2) glycerophospholipids, including phosphatidylcholines;
(3) eicosanoids, some of which were negatively associated with
large for gestational age; and (4) a ratio of two positively and
two negatively associated metabolites that predicted
intrauterine growth restriction at term.
Added value of this study
To facilitate a more comprehensive evaluation of how the
maternal exposome influences the biology of early human
growth and development, we analysed the relationships
between size at birth and: maternal metabolite signatures

pre-pregnancy and intergenerational effects, than genetic
factors alone,6 because growth and neurodevelopmental
patterns from conception to early childhood are similar
across geographically diverse populations that have
adequate health, nutrition, education, and breastfeeding.7,8
Thus, the complexity of size at birth and its influence on
later life are best understood by considering how the
maternal exposome influences the biology of early
human growth and development.9
Here, we aimed to study, in a large multinational
pregnancy cohort, the relationships between: (1) maternal
metabolite signatures (as a measure of the exposome);
(2) ultrasound-derived fetal abdominal circumference
trajectories and their feto–placental blood flow patterns;
and (3) postnatal growth, adiposity, and neuro
development.

Methods

Study design and participants
The prospective, multinational, observational INTERBIO21st fetal study was conducted in maternity units in
Pelotas (Brazil), Nairobi (Kenya), Karachi (Pakistan),
Soweto (South Africa), Mae Sot (Thailand), and Oxford
(UK) between Feb 8, 2012, and Nov 30, 2019.10 We enrolled
3598 women who initiated antenatal care before 14 weeks’
gestation, identified by ultrasound dating,11 and monitored
their pregnancies to delivery. Their children’s health,
growth, and development were monitored until the age of
2 years; a corrected age was used for infants who were
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022

(as a measure of the exposome); four fetal phenotypes
(ultrasound-derived, abdominal circumference trajectories, and
their feto–placental blood flow patterns); and postnatal
growth, adiposity, and neurodevelopment. These distinct fetal
phenotypes had different growth, adiposity, vision, and
neurodevelopment outcomes in early childhood. The extreme
phenotypes (faltering growth and early accelerating growth)
had a significant reciprocal relationship with a set of
early-pregnancy maternal metabolite signatures: 5-hydroxyeicosatetraenoic acid and 11 phosphatidylcholines linked to
oxylipin or saturated fatty acid side-chains.
Implications of all the available evidence
Understanding how the maternal exposome influences early
human development requires deep phenotyping to
complement clinical classifications of complex perinatal
syndromes, such as SGA and preterm birth. We have identified
putative metabolic pathways responsible for the strong
association between distinct trajectories of fetal growth and
childhood health outcomes. Routine identification of the
described trajectories for abdominal circumference, in addition
to head circumference trajectories, and the timing of their
divergence, should be incorporated into the diagnosis of fetal
growth restriction.

born preterm. The inclusion criteria for the women were:
being 18 years or older, a BMI of less than 35 kg/m²,
natural conception, and singleton pregnancy. A sample of
non-fasting venous blood was obtained at the earliest
possible opportunity, at a median (IQR) gestational age of
13·2 weeks (11·9–17·2), plus a sample of umbilical cord
venous blood at delivery; all samples were processed and
stored as per protocol.12
The study was approved by the Oxfordshire Research
Ethics Committee, the research ethics committees of the
participating institutions, and their regional health
author
ities. All mothers provided written informed
consent.

Procedures
After the dating ultrasonography, the women underwent
an ultrasonography every 5±1 weeks until delivery using
identical equipment (Philips HD-9, Philips Ultrasound,
Andover, MA, USA). The methods to measure abdom
inal circumference growth have previously been
described.13 From 22 weeks’ gestation, the umbilical
artery Doppler Pulsatility Index, a marker of feto–
placental perfusion, was measured. Mean umbilical
artery Doppler Pulsatility Index values were expressed as
z-scores of the international standard (reference).14 The
anthropometric measure
ment meth
ods used have
previously been described.15 Infant age-specific and sexspecific z-scores and centiles were compared with the
WHO Child Growth Standards.16
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We assessed neurodevelopment at the age of 2 years
using the INTERGROWTH-21st Neurodevelopmental
Assessment (INTER-NDA), a multicultural, psychometric
tool for children aged 22–30 months, designed to be
implemented by non-specialists across international set
tings, which measures multiple dimensions of early
development using directly administered, concurrently
observed, and caregiver reported items.17 Metabolite
signatures were measured using untargeted mass
spectrometry (Sapient Bioanalytics, San Diego, CA, USA)
and compound identification was performed by spectral
matching to open access and private spectral databases.
To visualise the metabolite feature data, we used Uniform
Manifold Approximation and Projection (UMAP) with
the Python package UMAP-learn.18 For more details of
the metabolomic analysis, see the appendix (pp 3–5).

Statistical analysis and outcomes
To establish the abdominal circumference growth
trajectories (the primary outcome of the study), we
constructed models for the repeated measurement of
abdominal circumference z-scores using finite mixture
models.19 Group mean growth patterns were modelled
using Gaussian distributions by applying a quadratic
B-spline with one internal knot placed at the median.20
A z-score of 0 at 10 weeks’ gestation for each infant was
added to highlight the growth trajectories relative to the
initial ultrasonography and prevent grouping strictly by
size. All mixture modelling was done using the hlme
function of the R package lcmm.21,22
Posterior group probabilities for models with three to
five growth pattern groups were estimated,23 allowing for
a low number of trajectories following recognised fetal
growth patterns. Trajectories were established using only
fetal measures without considering their 2-year outcomes
or metabolomic data, to which the statistician (SAR) was
masked during the analysis. The optimal number of
groups for each growth measure was selected on the
basis of the best model fit using the Bayesian Information
Criterion, and the number of infant in the smallest group
that comprised at least 2·5% of the total sample. Every
infant received a posterior probability of being in each
group and was then assigned to the definitive group with
the highest probability (appendix p 9).
Abdominal circumference growth trajectories comprised
the primary independent variables. The trajectory tracking
the 50th centile of the INTERGROWTH-21st standard13
was the reference group. Outcomes from the neuro
developmental assessment were based on normative
INTER-NDA scores.17,24 Categories of low visual acuity
(logarithm of the Minimum Angle of Resolution [logMAR]
>0·4) and high contrast sensitivity (>3%) were based on
Cardiff normal values.25
We used linear regression models to assess the
relationships with continuous and normally distributed
measures of growth, cognition, language, and fine motor
and gross motor domains stratified by the duration of
712

any breastfeeding (<7 months or ≥7 months). The
positive affect domain was reverse coded, and both
positive and negative scales were modelled as count
data using generalised linear models, with a Poisson
distribution and log-link function and a variance
correction for over-dispersion. Vision outcomes were
modelled as binary variables using Poisson regression
with robust standard errors because they were not rare
outcomes and negative binomial regression models
often did not converge. The results represent a change in
score or relative risk for each trajectory compared with
the reference median growth trajectory. A p value of less
than 0·05 was deemed statistically significant. We
corrected our results for multiple comparisons using the
Benjamini-Hochberg False Discovery Rate correction to
control for type 1 error rate at <0·05.
We selected covariates suspected a priori to be in the
causal pathway, using separate directed acyclic graphs for
growth and neurodevelopmental outcomes (appendix
p 21). In all adjusted models, we included the infant’s sex
and age at assessment, preterm birth, maternal age,
maternal education, and smoking during pregnancy. As
done previously,26 we conducted a primary stratified
analysis to evaluate the effect modification by the duration
of breastfeeding (<7 months or ≥7 months). We included
abdominal circumference and head circumference trajec
tories in the models to explore the independent effect of
abdominal circumference phenotypes.10
All analyses were performed using R (version 3.6.0;
The R Core Team, Vienna, Austria) and STATA
(version 15.1; StataCorp, College Station, TX, USA).

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.

Results
Of the 5301 women screened, we enrolled 3598 between
Feb 8, 2012, and Nov 30, 2019. Of these, 3206 had three or
more scans between 14 and 37 weeks’ gestation (mean,
4·7 scans) and thus were included in the study. Each
site’s contribution to the total sample were: 397 (12·4%)
of 3206 from Pelotas (Brazil), 647 (20·2%) from Oxford
(UK), 554 (17·3%) from Soweto (South Africa),
502 (15·7%) from Karachi (Pakistan), 530 (16·5%) from
Mae Sot (Thailand), and 576 (18·0%) from Nairobi
(Kenya). There were 24 stillbirths or terminations
resulting in 3182 eligible for birth outcomes. There were
21 deaths and 279 children excluded as they were older
than 1 year when the neurodevelopmental assessments
began, resulting in 2882 eligible for the 1 year assessment.
There were 439 losses to follow-up, resulting in
2443 children assessed at 1 year (85% of those eligible). At
the 2 year follow-up there were three additional deaths,
nine missing all year outcomes and 446 lost to follow-up.
However, 198 children who attended the 2-year visit did
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022
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0
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–1·0

B
1·5
Abdominal circumference
and weight-for-length z-score

not attend the 1-year visit, leaving 2886 children eligible
for the 2 year assessment. Overall, 2183 children
completed the 2-year follow-up (76% of those eligible;
appendix p 20).
The best fitting model of abdominal circumference
growth had four trajectories (figure 1). The reference
group was the median growth tracking (n=1166)
phenotype with a growth pattern close to the 50th centile
of the INTERGROWTH-21st standard.13 The faltering
growth (n=763) phenotype showed abdominal circum
ference growth decreasing from early pregnancy to
20–23 weeks’ gestation; thereafter, the trajectory stayed at
slightly less than –1 SD of the standard. The late
accelerating growth (n=773) phenotype showed accel
erating growth from 25 weeks’ gestation that was slightly
less than +1 SD of the standard by 35 weeks’ gestation.
The early accelerating growth (n=504) phenotype showed
a rapid early growth that reached +1·5 SD of the standard
by 20–25 weeks’ gestation and thereafter mirrored the
faltering growth phenotype (figure 1).
For each abdominal circumference phenotype we
assessed the following measures: (1) abdominal cir
cumference measured between the gestational age of
15–20 weeks and 25–30 weeks; (2) birthweight for
gestational age and sex expressed as a z score of the
INTERGROWTH-21st standard;13,15 and (3) weight for age
and sex and weight-for-length for age and sex at age
1 and 2 years, all expressed as z-scores of the WHO Child
Growth Standards16 (figure 2; appendix pp 10–11).
Overall, from the second trimester of pregnancy to age
2 years, the faltering growth and early accelerating
growth phenotypes were separated by the median growth
tracking and late accelerating growth phenotypes
(figure 2A). A similar pattern was observed for weightfor-length at ages 1 and 2 years, as a measure of early
childhood adiposity (figure 2B); however, there was a
slight upwards shift across the four pheno
types,

0·5

–1·5

40

Gestational age (weeks)

Figure 1: Fetal abdominal circumference growth phenotypes in the
INTERBIO-21st fetal study (n=3206)
Shaded bands represent 95% CIs for the splines used to summarise group
trajectories.

1·0

1·0
0·5
0
–0·5
–1·0
–1·5

15–20
weeks

25–30
weeks

Birth

1 year

2 years

Figure 2: Growth z-scores for abdominal circumference during pregnancy,
and weight (A) and weight-for-length (B) at birth and 1 and 2 years in the
INTERBIO-21st fetal study
Measurements up until birth (15–20 weeks’ gestation and 25–30 weeks’
gestation) were of abdominal circumference, and subsequently were either of
weight (A) or weight-for-length (B). Fetal measurements of abdominal
circumference were from the ultrasound scans. Error bars represent the 95% CIs
of the means.

indicative of a greater increase in weight attainment in
proportion to height, particularly for the faltering growth
phenotype. Ultrasound-derived estimated fetal weight
showed almost identical patterns to both weight and
weight-for-length at age 1 and 2 years (data not shown).
Mothers of children in the faltering growth phenotype
tended to be shorter and less educated, had lower prepregnancy BMI, and a higher rate of smoking and
preeclampsia (appendix p 16). The mothers of children in
the late accelerating growth and early accelerating growth
phenotypes tended to have overweight or obesity, and
have gestational diabetes and pregnancy-induced
hypertension (appendix p 15).
The median growth tracking and faltering growth
phenotypes had a similar mean (SD) duration of breast
feeding: 13·1 (8·8) months for median growth tracking
versus 13·9 (8·8) months for faltering growth (p=0·08).
The early accelerating growth (11·1 [8·4] months) and late
accelerating growth (12·6 [8·9] months) phenotypes had
slightly shorter durations than the median growth
tracking phenotype (p=0·002). Breastfeeding for 7 months
or more increased the postnatal growth patterns of
713
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Umbilical artery Doppler pulsatility
index z−score

Faltering growth (n=758)
Median growth tracking (n=1165)
Late accelerating growth (n=771)
Early accelerating growth (n=504)
1·0
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–0·5
–1·0

24
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32

34

36
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Gestational age (weeks)

Figure 3: Umbilical artery Doppler Pulsatility Index trajectories in the
INTERBIO-21st fetal study
N=3206. Group membership was established by an analysis of fetal abdominal
circumference growth trajectories. Shaded bands represent the 95% CIs for
splines used to summarise group trajectories.

weight, head circumference, and weight-for-length for
the faltering growth phenotype, without statistically
significant interactions between the two breastfeeding
strata. For the late accelerating growth and early
accelerating growth phenotypes, children breastfed for
7 months or more had significantly higher weight, larger
head circumference, and greater weight-for-length than
the median growth tracking phenotype; however, the
interaction terms by breastfeeding duration were not
significant (appendix pp 13, 17 ,22).
Finally, we assessed the association between the abdom
inal circumference phenotypes and neurodevelopmental
outcomes at 2 years, stratified by breastfeeding duration
(appendix pp 13, 17). The early accelerating growth phe
notype scored highest on the language and positive affect
domains of the INTER-NDA,24 only if infants were
breastfed for 7 months or more. The early accelerating
growth phenotype showed significantly lower risk for
poor vision outcomes at 2 years than the median growth
tracking phenotype, as expressed by low LogMAR for
visual acuity and low percentage for contrast sensitivity,25
regardless of breastfeeding duration. Conversely, the
faltering growth phenotype had the highest risk for poor
visual outcomes, but the risk for low acuity (high LogMAR
scores) was reduced among infants breastfed for 7 months
or more (appendix pp 14–15, 18–19).
There were 26 significant findings with abdominal
circumference growth trajectories related to 2-year out
comes, of which 24 (92%) were significant after correcting
for multiple comparisons; of these 24 significant findings,
nine were for late accelerating growth phenotypes and
10 were for early accelerating growth phenotypes, as well
as five of the seven significant findings for the faltering
growth phenotype.
We modelled the mean umbilical artery Doppler
Pulsatility Index values for each phenotype, expressed as
714

z-scores of the international standard.14 From 24 weeks’
gestation onwards, Doppler Pulsatility Index trajectories
for the faltering growth phenotype were consistently
higher than for the other three phenotypes, whose
95% CIs overlapped during the third trimester (figure 3).
Few maternal or umbilical cord venous metabolites
among the median growth tracking and late accelerating
growth phenotypes reached the strict criterion for statistical
significance (p<10–⁶) and, as a result, we decided to focus
our efforts on understanding the metabolic differences
between the most divergent growth trajectories (figure 1);
these two groups displayed more statistically significant
signatures when compared with the other groups. Figure 4
presents volcano plots of the odds ratio (OR) distributions
for each maternal metabolite according to the faltering
growth and early accelerating growth phenotypes esti
mated from logistic regression analysis, adjusted for
maternal age and newborn sex. These phenotypes were
associated with 709 statistically significant maternal
metabolites with positive effect for the faltering growth
phenotype and 54 metabolites (appendix pp 28–43) for the
early accelerating growth phenotype, and 31 statistically
significant maternal metabolites with negative effect
for the faltering growth phenotype and 76 metabolites
(appendix pp 43–45) for the early accelerating growth
phenotype (figure 4A and B). 33 metabolites (appendix p 46)
overlapped between the faltering growth and early accel
erating growth phenotypes, which were also associated
with 627 (for the faltering growth phenotype) and 1675 (for
the early accelerating growth phenotype) statistically
significant umbilical cord venous metabolites with positive
effect. These metabolites were also associated with 364
(for the faltering growth phenotype) and 1225 (for the early
accelerating growth phenotype) with negative effect
(figure 4C and D), with 604 over
lapping metabolites
(appendix pp 46–59).
We visualised how metabolites associated with these two
phenotypes diverged at the metabolome-wide level using
dimensional reduction with supervised Uniform Manifold
Approximation and Projection (appendix p 5),18 including
all detectable molecules. The data separated into
two clusters, indicating distinctive underlying metabolite
abundance profiles between the faltering growth and early
accelerating growth phenotypes in both maternal and
umbilical cord venous plasma (appendix p 24).
Figure 5 presents ORs (95% CI) for the 20 unique
molecules (p<10–⁶ identified that overlapped the faltering
growth and early accelerating growth phenotypes for
which we performed compound identification. Grouped
ORs (95% CI) represent unique molecules, either multiple
isotopes or adducts. Most metabolites associated with the
faltering growth phenotype had ORs close to 1·5, indicative
of an upregulation of metabolic pathways associated with
impaired fetal growth; conversely, these metabolites had
a reciprocal relationship with the early accelerating growth
phenotype, which suggests that the same pathways are
downregulated when fetal growth is accelerated.
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022
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Discussion
In this primary analysis of the INTERBIO-21st fetal study,
we present longitudinal abdominal circumference
phenotypes associated with different patterns of feto–
placental blood flow (reflecting the varied placental transfer
of essential nutrients); birthweight; postnatal weight,
weight-for-length, and visual and neuro
developmental
scores up to age 2 years; and maternal and newborn baby
metabolite signatures.
Abdominal circumference was evaluated as the main
independent variable principally because it approximates
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022
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Among the 20 unique metabolite annotations over
lapping the faltering growth and early accelerating growth
phenotypes, seven were uncharacterised molecules; one
was an eicosanoid (5-HETE) and 11 were phosphatidyl
cholines (five with oxylipin and six with palmitic acid
as the most common sidechains). We also identified
hydroxy-chlorothalonil, a metabolite of the fungicide,
chlorothalonil, in a positive association with the early
accelerating growth phenotype (figure 5).
We selected the top ten metabolite annotations for each
positively and negatively associated with the faltering
growth and early accelerating growth phenotypes (n=40);
of these, 30 (faltering growth=14 and early accelerating
growth=16) were distinct from the 33 metabolite anno
tations that overlapped the two phenotypes. Among the
14 that were exclusive to the faltering growth phenotype,
an additional five phosphatidylcholines were identified.
Of these, four had a positive association with the faltering
growth phenotype and contained oxylipin or the oxylipin
precursors docosahexaenoic acid and hydroperoxylinoleic
acid as a sidechain, along with saturated fatty acids
(eg, stearic or palmitic acid) as the other sidechain. The
fifth phosphatidylcholine, with a saturated fatty acid
sidechain (1-decanoyl-2-heneicosanoyl-sn-glycero-3-phos
phocholine), had a negative association with the faltering
growth phenotype. Additionally, threonine (or homoser
ine), the precursor of the amino acids glycine and serine,
was putatively identified as positively associated with the
faltering growth phenotype. All 16 metabolite annotations
that were exclusive to the early accelerating growth
phenotype were not identified.
We compared metabolites identified in both the maternal
and umbilical cord venous samples. In the faltering growth
phenotype, 603 molecules were associated with both
sample sets, of which 47 were significant (p=8·3 × 10–⁵). In
the early accelerating growth phenotype, 107 molecules
were associated with both sample sets, of which 31 were
significant (p=4·6 × 10–⁴). However, only two metabolites
overlapped the faltering growth and early accelerating
growth phenotypes in the maternal and umbilical cord
venous cord samples, and these uncharacterised
metabolites were positively associated with the faltering
growth phenotype. Hydroxyl-chlorothalonil was also
observed in cord blood samples, but was not significantly
associated with any growth trajectory (data not shown).
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accelerating growth phenotypes of ultrasound-based fetal abdominal circumference growth trajectories
(n=2713 women and n=2430 newborn babies). Blue dots indicate p<10–⁶.

the growth of the fetal liver and abdominal subcutaneous
fat. Hepatic volume in uncomplicated pregnancies
increases 10 times from 20 to 36 weeks’ gestation; in
growth-restricted fetuses, the fall in z-scores for
abdominal circumference and hepatic volume is similar.27
Thus, we identified, across a key period of human
development, organ-specific novel phenotypes or socalled exposotypes.28 This concept is central to our efforts
to create a functional classification of fetal growth
alterations with substantial effects during childhood,
rather than mere biometrically based descriptions.
Our findings, based on a systems biology approach,
add to the existing evidence that understanding the
influence of the maternal exposome on human
development from early pregnancy onwards requires
much deeper phe
notyping to complement syndromic
classifications, such as preterm birth.9,12 Our approach
has identified not only a strong association between
distinct trajectories of fetal growth and childhood
outcomes, but also the putative metabolic pathways that
cause the biological mechanisms.
In addition, one of our key observations, with consid
erable biological and programmatic implications, is the
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existence of an important developmental window at
20–25 weeks’ gestation. During this period, fetal growth
patterns emerge that appear to be organ-specific: after
an initial period of accelerated or deaccelerated growth,
abdominal circumference measures start to stabilise,
just as head circumference growth starts accelerating or
deaccelerating (appendix p 27). We acknowledge that we
did not find a significant interaction between
breastfeeding and postnatal growth in the context of
this early pregnancy effect; however, understanding the
biological implications of these interactions is the aim
of our ongoing analyses.
The faltering growth phenotype, in particular, showed
early growth restriction and reduced feto–placental blood
flow throughout pregnancy, without postnatal catch-up
growth. These observations and the maternal
characteristics of mothers of children in the faltering
growth phenotype suggest that fetuses and children that
follow the faltering growth pattern are not simply
constitutionally small, and there is a faltering growth
phenotype subgroup, associated with preeclampsia and
reduced umbilical artery flow, that manifests early in
pregnancy. Conversely, the late accelerating growth and
early accelerating growth phenotypes were associated
with the metabolic syndrome, overweight and obesity,
gestational diabetes, or pregnancy-induced hypertension).
Hence, the variability seen in fetal hepatic growth and
subcutaneous fat deposition needed for postnatal
thermoregulation as seen in figure 1, is related to specific
risk and exposome factors that persist in affecting growth
up to 2 years. In infants with the faltering growth
phenotype, postnatal adiposity steadily increased, as seen
in figure 2B, mostly because of a slower growth in length
rather than a faster increase in weight. It is likely,
therefore, that an adverse maternal exposome early in
pregnancy, when skeletal growth velocity is at its
highest,29 has a lasting effect on infant length and height
716

and adiposity, which might also explain why a mismatch
between faltering abdominal circumference growth and
rapid postnatal weight gain is associated with elevated
insulin resistance, fat accumulation, and high blood
pressure in early childhood.30
Our metabolomic analyses show that few maternal
metabolites are associated with abdominal circumference
trajectories that diverge early in pregnancy. The
metabolite hydroxy-chlorothalonil in maternal plasma
had a signifi
cant reciprocal association with the two
extreme abdominal circumference phenotypes, as shown
in figure 5. This association was similar in the umbilical
cord venous samples (although not significantly),
supporting the placental transfer of chlorothalonil as
previously reported.31 However, the mechanism by which
this fungicide, which was banned in Europe in 2020,
might stimulate fetal growth is unclear.
Five (oxylipin [HDoHE] palmitic acid, oxylipin [HDoHE]
stearic acid, oxylipin [HETE] palmitic acid, oxylipin
[HETE] stearic acid, and oxylipin [22:5;0] palmitic acid) of
the 11 overlapping phos
phatidylcholines between the
faltering growth and early accelerating growth
phenotypes, as shown in figure 5, and four of those
exclusively related to the faltering growth phenotype
(PC [36:4;O3], PC [18:0/20:4;O2] stearic acid or DiHETE,
PC [16:0/22:6] palmitic acid, and PC [16:0/18:2;O2]
palmitic acid or hydroperoxylinoleic acid), had either
saturated fatty acids or oxylipin as sidechains. Of the
four phosphatidylcholines that were overlapping but with
a higher abundance in the faltering growth phenotype,
three (PC [38:7;O2] or PC(35:2;O4), hexadecenoic acid or
linoleic acid, and hexadecenoic acid or arachidonic acid or
palmitic acid) had a palmitic acid or palmitoleic acid
sidechain, or pentacosanoic acid sidechain, a very longchain saturated fatty acid; the fourth phosphatidylcholine
(38:1;O) was linked to a sphingolipid, which has been
associated with cardiovascular events and SGA.32,33 Of the
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022
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two phosphatidylcholines with a higher abundance in the
early accelerating growth phenotype, one had the satu
rated heptadecenoic acid (margaric acid) and the other
a long-chain fatty acid (putative 34:5).
We speculate that an explanation for the reciprocal
association of oxylipins linked to phosphatidylcholines is
that they function as endogenous signalling molecules,
serving as ligands for nutrient-sensing peroxisome
proliferator-activated receptors (PPARs).34 All three PPAR
isotypes are highly expressed in placental tissue throughout
pregnancy and play a key role in trophoblast differentiation
and regulating energy metabolism, organ growth, and
adipose deposition in the fetus.35 There is in vitro evidence
that the activation of PPARs alters placental function
by downregulating 11β-hydroxysteroid dehydrogenase
type 2 expression.36 Placental 11β-hydroxysteroid dehydro
genase type 2 reduces the deleterious effects of fetal
expo
sure to maternal glucocorticoids, and reduced
expression of this enzyme is associated with intrauterine
growth restriction.37
Alternatively, oxylipins, which are a broad range of
oxidised lipids derived from polyunsaturated fats, might
be affecting placental function via inflammation and
oxidative stress.38 Likewise, saturated fatty acids might
affect placental function because they induce trophoblast
lipoapoptosis in vitro, a cause of programmed cell death.39
Thus, the balance between saturated fatty acids and
polyunsaturated fatty acid phosphatidylcholine sidechains
might establish the trajectory of early fetal growth.
Conclusions drawn from metabolomic studies about the
specific effects of oxylipins and phosphatidylcholines in
pregnancy, most of which are dependent on maternal diet,
are speculative given the heterogeneity of these compounds
and the complexity of lipid biology. Summarising this
literature is also difficult because multiple pregnancy
outcomes have been explored, and there are well recog
nised limitations to metabolomic studies, including the
low reproducibility of results and inconsistent reporting
practices, precluding formal meta-analysis.40
An initial inspection of the results from our formal
systematic review of metabolomic studies in pregnancy,41
which builds on a previous review,42 has identified
16 unique studies presenting data on metabolomic
markers of lipid metabolism associated with SGA,
intrauterine growth restriction, and fetal growth restric
tion; only four collected maternal blood samples early in
pregnancy. The SCOPE cohort study found glyc
erophospholipids, including phosphatidylcholines, to be
associated with SGA.33,43 Welch and colleagues44 identified
eicosanoids to be positively associated with SGA, some
of which were negatively associated with large for
gestational age (LGA). Sovio and colleagues45,46 showed
that a ratio of two positively and two negatively associated
metabolites predicted intrauterine growth restriction at
term, as well as LGA, and that it is inversely associated
with birthweight. Finally, McBride and colleagues47
reported an association between different alterations in
www.thelancet.com/diabetes-endocrinology Vol 10 October 2022

lipid biology and SGA; however, they used targeted
nuclear magnetic resonance, which identifies fewer
metabolites. McBride and colleagues48 also analysed
samples taken later in pregnancy (26–28 weeks’
gestation), and showed that 4-hydroxyglutamate and
glycerol combined with maternal risk factors improved
the prediction of SGA and LGA.
In summary, this well powered, primary analysis of the
INTERBIO-21st fetal study provides uniquely robust
information because we followed a large, prospective
cohort from low-income, middle-income, and highincome countries at moderate or high risk of pregnancy
and postnatal complications from early pregnancy to age
2 years; all pregnancies were accurately dated by
ultrasonography and early infant feeding was humanmilk based. Dedicated research staff obtained ultrasound
and postnatal standard anthropometric measures using
the same equipment. We transformed all measures to
z-scores of international standards, allowing multiple
regression analyses to be conducted across time using
the same conceptual framework. Finally, our large
sample size and longitudinal study design allowed us to
explore several variables in the causal pathway that are
often matched in small case–control studies.
There are limitations intrinsic to statistical analysis
covering such a range of variables and unit measures. Our
phenotypic modelling methods could only approximate
the abdominal circumference trajectories’ starting point
early in pregnancy and these methods were specific to our
cohort, although future studies could use the same
methods. The visual representation in the appendix (p 24)
needs to be interpreted with caution, avoiding overinterpretation, because the dimensionality reduction tech
nique Uniform Manifold Approximation and Projection is
not quantitative; the algorithm simply optimises the
visualisation of the data separation using phenotypic
labels. Most biomolecules were in low abundance but
the metabolomic analyses were conducted using relative,
rather than absolute, abundance concen
trations (ie,
qualitative differences). We might have missed other
important metabolites because of selection bias occurring
when isolating metabolites for measurement. We could
not establish the precise polyunsaturated fatty acid
derivation of the oxylipins identified, which particles the
phosphatidylcholines were associated with, and the
directionality of signalling (ie, to or from the placenta),
which we believe is important because metabolites derived
from essential fatty acids are well conserved. Nor was it
possible to elucidate all the biological pathways involved
because many molecules were uncharacterised. Of note,
however, is that both positive and negative method data
were collected, which expanded the pool of metabolites
observed. Our four-trajectory model was data driven,
based on criteria defined a priori. The faltering growth
group could possibly be further subclassified49 according
to the timing of deceleration, but this was problematic
because group membership was specific to the model
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used and splitting the faltering growth group post-hoc
would be inadvisable. Lastly, the use of middle cerebral
artery Doppler to capture the so-called brain-sparing
effect,50 in addition to umbilical artery Doppler as a mea
sure of feto–placental blood flow, could have provided
further characterisation of the groups.
We have presented results stratified by breastfeeding
duration, which can introduce bias by treating potentially
mediating variables as effect modifiers if faltering growth
infants are breastfed for shorter periods; however, this
was not the case in our cohort. Hence, we present both
stratified and overall results because breastfeeding
duration is known to be an effect modifier for infant
growth and development, and more importantly, if
confirmed, it has considerable relevance clinically and
for public health generally.
Overall, our present and past results13 (appendix p 27)
strongly support the existence of: (1) organ-specific
patterns of fetal growth trajectories that follow distinct
growth, adiposity, and visual and neurodevelopmental
outcomes in early childhood; (2) the influence of
breastfeeding on these patterns; (3) a crucial window at
20–25 weeks’ gestation when the growth of the fetal
cranium and abdomen can accelerate or decelerate,
resulting in sustained trajectories; and (4) a strong
association between restricted abdominal circumference
growth, reduced utero–placental blood flow, and the
maternal exposome involving phospholipid metabolism,
linked to postnatal growth trajectories.
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